CoChat

Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system

Open access

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Abstract

Non-alcoholic steatohepatitis (NASH) is a common form of chronic liver disease characterised by lipid accumulation, infiltration of immune cells, hepatocellular ballooning, collagen deposition and liver fibrosis. There is a high unmet need to develop treatments for NASH. We have investigated how liver fibrosis and features of advanced clinical disease can be modelled using an in vitro microphysiological system (MPS). The NASH MPS model comprises a co-culture of primary human liver cells, which were cultured in a variety of conditions including+/- excess sugar, fat, exogenous TGFβ or LPS. The transcriptomic, inflammatory and fibrotic phenotype of the model was characterised and compared using a system biology approach to identify conditions that mimic more advanced clinical disease. The transcriptomic profile of the model was shown to closely correlate with the profile of patient samples and the model displayed a quantifiable fibrotic phenotype. The effects of Obeticholic acid and Elafibranor, were evaluated in the model, as wells as the effects of dietary intervention, with all able to significantly reduce inflammatory and fibrosis markers. Overall, we demonstrate how the MPS NASH model can be used to model different aspects of clinical NASH but importantly demonstrate its ability to model advanced disease with a quantifiable fibrosis phenotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42003-021-02616-x

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Liver MPS NASH model demonstrates fibrotic phenotype. PHH alone (Control and Steatosis) or PHH, KC and HSC co-cultures (NASH) were cultured in the MPS platform for 14 days under standard media (control) or high fat conditions (Steatosis and NASH). a Liver microtissues were stained for cytoskeleton (phalloidin), collagen-type I and α-SMA and imaged by confocal microscopy. Representative images shown and scale bars 200 µm. b Staining of microtissue was quantified by measuring total fluorescence intensity throughout individual microtissues, each data point represents an average of all microtissues within a FOV (min 8, max 12) and two FOV per scaffold. c Secreted fibrosis biomarkers TIMP-1, Pro-collagen 1, YKL-40 and Fibronectin were all measured in cell culture medium by ELISA, at the end of the culture. d The expression of fibrosis genes was analysed in total RNA from steatosis and NASH models using Human Fibrosis RT2 Profiler PCR Arrays. Gene expression levels are expressed as Log10 relative expression compared to housekeeping genes (GAPDH/B2M/HPRT1) and compared between the NASH and steatosis models (red = upregulation, green = downregulation, black = no change, upper line—1.5-fold increase, lower line 1.5-fold decrease). All data points shown with means ± SD highlighted, data generated from a minimum of nine independent cultures (three donors per condition and n = 3 per donor).
Fig. 1 Liver MPS NASH model demonstrates fibrotic phenotype. PHH alone (Control and Steatosis) or PHH, KC and HSC co-cultures (NASH) were cultured in the MPS platform for 14 days under standard media (control) or high fat conditions (Steatosis and NASH). a Liver microtissues were stained for cytoskeleton (phalloidin), collagen-type I and α-SMA and imaged by confocal microscopy. Representative images shown and scale bars 200 µm. b Staining of microtissue was quantified by measuring total fluorescence intensity throughout individual microtissues, each data point represents an average of all microtissues within a FOV (min 8, max 12) and two FOV per scaffold. c Secreted fibrosis biomarkers TIMP-1, Pro-collagen 1, YKL-40 and Fibronectin were all measured in cell culture medium by ELISA, at the end of the culture. d The expression of fibrosis genes was analysed in total RNA from steatosis and NASH models using Human Fibrosis RT2 Profiler PCR Arrays. Gene expression levels are expressed as Log10 relative expression compared to housekeeping genes (GAPDH/B2M/HPRT1) and compared between the NASH and steatosis models (red = upregulation, green = downregulation, black = no change, upper line—1.5-fold increase, lower line 1.5-fold decrease). All data points shown with means ± SD highlighted, data generated from a minimum of nine independent cultures (three donors per condition and n = 3 per donor).CC BY · PubMed Central
Fig. 2 Transcriptional profile of NASH liver MPS model aligns with profile from human clinical samples. PHH, KC and HSC co-cultures were cultured in the MPS platform under high fat conditions for 14 days and total RNA extracted and analysed by RNAseq to determine overall transcriptomic profile. Transcriptional profile of liver NASH MPS compared to the a Human gene atlas and b the DISEASES database using the Enricher gene enrichment analysis tool (maayanlab.cloud/Enrichr/)68. 300 highest expressed DEGs in the NASH model were compared to control PHH samples, ranking by p value (probability of genes being associated with the gene set. c Breakdown of Top 100 genes expressed in liver MPS NASH model. d, e Published studies identify key differentially expressed genes specifically in NAFLD/NASH patient samples. d Advanced vs mild fibrosis in NAFLD30, e NASH vs NAFLD vs obese control17. Heatmaps demonstrate Log2 fold change in transcripts for these genes in transcriptome from liver MPS NASH model compared to control PHH samples. f Comparison of correctly overlapping DEGs in NASH pre-clinical models, murine models from literature17 and NASH MPS model (data from e). Transcriptomic data were generated from nine independent replicate samples and averaged.
Fig. 2 Transcriptional profile of NASH liver MPS model aligns with profile from human clinical samples. PHH, KC and HSC co-cultures were cultured in the MPS platform under high fat conditions for 14 days and total RNA extracted and analysed by RNAseq to determine overall transcriptomic profile. Transcriptional profile of liver NASH MPS compared to the a Human gene atlas and b the DISEASES database using the Enricher gene enrichment analysis tool (maayanlab.cloud/Enrichr/)68. 300 highest expressed DEGs in the NASH model were compared to control PHH samples, ranking by p value (probability of genes being associated with the gene set. c Breakdown of Top 100 genes expressed in liver MPS NASH model. d, e Published studies identify key differentially expressed genes specifically in NAFLD/NASH patient samples. d Advanced vs mild fibrosis in NAFLD30, e NASH vs NAFLD vs obese control17. Heatmaps demonstrate Log2 fold change in transcripts for these genes in transcriptome from liver MPS NASH model compared to control PHH samples. f Comparison of correctly overlapping DEGs in NASH pre-clinical models, murine models from literature17 and NASH MPS model (data from e). Transcriptomic data were generated from nine independent replicate samples and averaged.CC BY · PubMed Central
Fig. 3 Obeticholic acid and Elafibranor both modulate inflammatory and fibrosis phenotype in liver MPS NASH model and phenotype can additionally be reversed with dietary changes. PHH, KC and HSC co-cultures were cultured in the MPS platform under high fat conditions and dosed with varying concentrations of Obeticholic acid (OCA) and Elafibranor (ELF) QD or vehicle control (control) for 10 days, following an initial 4-day pre-culture phase. a The secreted cytokine profile from liver microtissues was compared by Luminex to determine the effects of each compound on the inflammatory profile of the liver with samples analysed at day 8 and 14 of the culture. Data were normalised by Z-transformation to allow comparison of all analytes and presented as a heatmap. b The expression of fibrosis-associated genes was analysed in total RNA from control, OCA and ELF treated liver microtissues (highest concentration for each compound) using Human Fibrosis RT2 Profiler PCR Arrays. Gene expression changes are expressed as a fold change over control. c Liver microtissues were stained for collagen-type I, α-SMA, nuclei (DAPI - blue), phalloidin (green) and imaged by confocal microscopy. Representative images are shown and scale bars 200 µm. d Staining of microtissue was quantified by measuring total fluorescence intensity throughout individual microtissues, each data point represents an average of all the microtissues imaged within an MPS scaffold (min 8, max 20 microtissues). e PHH, KC and HSC co-cultures were cultured in the MPS platform under high fat or lean conditions for 30 days. Cultures either remained in the same type of media throughout or were switched at day 15 from fat media to lean media (Fat -> Lean). Cell culture medium samples were analysed for the presence of IL-6, f MCP-1, g TIMP-1, which were measured by ELISA. h Microtissues were stained with Oil-Red O to determine fat loading during culture period, total stain was quantified by absorbance at 510 nm. All datapoints shown, either as box-whisker plots highlighting mean and min-max or with error bars highlighting means ± SD. All data from a minimum of three independent cultures; statistical comparisons made to control samples unless other comparison shown.
Fig. 3 Obeticholic acid and Elafibranor both modulate inflammatory and fibrosis phenotype in liver MPS NASH model and phenotype can additionally be reversed with dietary changes. PHH, KC and HSC co-cultures were cultured in the MPS platform under high fat conditions and dosed with varying concentrations of Obeticholic acid (OCA) and Elafibranor (ELF) QD or vehicle control (control) for 10 days, following an initial 4-day pre-culture phase. a The secreted cytokine profile from liver microtissues was compared by Luminex to determine the effects of each compound on the inflammatory profile of the liver with samples analysed at day 8 and 14 of the culture. Data were normalised by Z-transformation to allow comparison of all analytes and presented as a heatmap. b The expression of fibrosis-associated genes was analysed in total RNA from control, OCA and ELF treated liver microtissues (highest concentration for each compound) using Human Fibrosis RT2 Profiler PCR Arrays. Gene expression changes are expressed as a fold change over control. c Liver microtissues were stained for collagen-type I, α-SMA, nuclei (DAPI - blue), phalloidin (green) and imaged by confocal microscopy. Representative images are shown and scale bars 200 µm. d Staining of microtissue was quantified by measuring total fluorescence intensity throughout individual microtissues, each data point represents an average of all the microtissues imaged within an MPS scaffold (min 8, max 20 microtissues). e PHH, KC and HSC co-cultures were cultured in the MPS platform under high fat or lean conditions for 30 days. Cultures either remained in the same type of media throughout or were switched at day 15 from fat media to lean media (Fat -> Lean). Cell culture medium samples were analysed for the presence of IL-6, f MCP-1, g TIMP-1, which were measured by ELISA. h Microtissues were stained with Oil-Red O to determine fat loading during culture period, total stain was quantified by absorbance at 510 nm. All datapoints shown, either as box-whisker plots highlighting mean and min-max or with error bars highlighting means ± SD. All data from a minimum of three independent cultures; statistical comparisons made to control samples unless other comparison shown.CC BY · PubMed Central
Fig. 4 Systems biology interrogation of liver MPS NASH model to determine physiologically relevant cues that promote transcriptional changes to mimic advanced NASH disease state. PHH, KC and HSC co-cultures were cultured in the MPS platform under a variety of conditions for 14 days and transcriptomic profile of microtissues were compared. a Study was designed to test number of NPCs, presence of fat, fructose, cholesterol, LPS and TGFβ for effects on the transcriptional profile of the liver MPS NASH model. b Differentially expressed genes (defined by comparison to low NPC lean) from selected conditions were compared to identify enriched pathways and biological processes, using PANTHER database and mapped using CompareCluster, with size of cluster representing number of genes involved (GeneRatio) and colour identifying confidence interval (p.adjust). Only high NPC conditions shown (low NPC data in Supp. Fig. 8) and some conditions did not produce any gene clusters with significant p value < 0.05 and are not shown on plot. c Expression of markers of NAFLD activity score progression45. d Expression of markers of fibrosis stage progression in NAFLD45. e Expression of liver-specific genes46. Heat maps used to compare different culture conditions with data normalised to z-scores to show variance from mean of all observations for each gene. Transcriptomic data were generated from a minimum of three independent replicate samples per condition.
Fig. 4 Systems biology interrogation of liver MPS NASH model to determine physiologically relevant cues that promote transcriptional changes to mimic advanced NASH disease state. PHH, KC and HSC co-cultures were cultured in the MPS platform under a variety of conditions for 14 days and transcriptomic profile of microtissues were compared. a Study was designed to test number of NPCs, presence of fat, fructose, cholesterol, LPS and TGFβ for effects on the transcriptional profile of the liver MPS NASH model. b Differentially expressed genes (defined by comparison to low NPC lean) from selected conditions were compared to identify enriched pathways and biological processes, using PANTHER database and mapped using CompareCluster, with size of cluster representing number of genes involved (GeneRatio) and colour identifying confidence interval (p.adjust). Only high NPC conditions shown (low NPC data in Supp. Fig. 8) and some conditions did not produce any gene clusters with significant p value < 0.05 and are not shown on plot. c Expression of markers of NAFLD activity score progression45. d Expression of markers of fibrosis stage progression in NAFLD45. e Expression of liver-specific genes46. Heat maps used to compare different culture conditions with data normalised to z-scores to show variance from mean of all observations for each gene. Transcriptomic data were generated from a minimum of three independent replicate samples per condition.CC BY · PubMed Central
Fig. 5 Systems biology interrogation of liver MPS NASH model to determine physiologically relevant cues that promote soluble biomarker changes to mimic advanced NASH disease state. PHH, KC and HSC co-cultures were cultured in the MPS platform under a variety of conditions for 14 days to test number of NPCs, presence of fat, fructose, cholesterol, LPS and TGFβ for effects on the soluble biomarker profile of the liver MPS NASH model. Expression of biomarkers, cytokines and chemokines were compared, all concentrations were normalised by Z-transformation to allow comparison and shown relative to mean for each marker (white = not detected). a Cytokine expression compared with varying levels of NPCs; b for the high NPC group in the presence of additional cues; c Expression of pro-fibrotic biomarkers with varying NPC content and with additional varying cues in high NPC condition (additional data in Supp. Fig. 17). d Graphical summary of the changes that occur in the NASH model in the presence of Fat and Fat + TGFβ. All data were generated from a minimum of three independent replicate samples per condition.
Fig. 5 Systems biology interrogation of liver MPS NASH model to determine physiologically relevant cues that promote soluble biomarker changes to mimic advanced NASH disease state. PHH, KC and HSC co-cultures were cultured in the MPS platform under a variety of conditions for 14 days to test number of NPCs, presence of fat, fructose, cholesterol, LPS and TGFβ for effects on the soluble biomarker profile of the liver MPS NASH model. Expression of biomarkers, cytokines and chemokines were compared, all concentrations were normalised by Z-transformation to allow comparison and shown relative to mean for each marker (white = not detected). a Cytokine expression compared with varying levels of NPCs; b for the high NPC group in the presence of additional cues; c Expression of pro-fibrotic biomarkers with varying NPC content and with additional varying cues in high NPC condition (additional data in Supp. Fig. 17). d Graphical summary of the changes that occur in the NASH model in the presence of Fat and Fat + TGFβ. All data were generated from a minimum of three independent replicate samples per condition.CC BY · PubMed Central
Fig. 6 Using enhanced liver MPS NASH model with TGFβ, Obeticholic acid and Elafibranor modulate disease phenotype to a greater extent than in standard NASH model. PHH, KC and HSC co-cultures were cultured in the MPS platform under high-fat conditions and dosed with varying concentrations of Obeticholic acid (OCA) and Elafibranor (ELF) QD or vehicle control for 10 days, following an initial 4-day pre-culture phase. Throughout the compound dosing period TGFβ was also dosed onto all microtissues (NASH only vehicle control samples were also included in the study for comparison, which were not treated with TGFβ or dosed with any compound). a The secreted cytokine profile from treated liver microtissues was compared to determine the effects of each compound on the inflammatory profile of the liver with samples analysed at day 8 and 14 of the culture. Data were normalised by Z-transformation to allow comparison of all analytes (white = undetected). b The expression of fibrosis-associated biomarkers was analysed on day 14 media samples and compared to NASH + TGFβ control samples. c Liver microtissues were stained for collagen-type I, α-SMA, nuclei (DAPI), phalloidin (green) and imaged by confocal microscopy. Representative images are shown and scale bars 200 µm. Staining of microtissues was quantified by measuring total fluorescence intensity throughout individual microtissues, each data point represents an average of all microtissues per MPS culture (min 8, max 20). All datapoints shown with error bars highlighting means ± SD, all data from a minimum of three independent cultures: all comparisons were made to NASH + TGFβ control samples.
Fig. 6 Using enhanced liver MPS NASH model with TGFβ, Obeticholic acid and Elafibranor modulate disease phenotype to a greater extent than in standard NASH model. PHH, KC and HSC co-cultures were cultured in the MPS platform under high-fat conditions and dosed with varying concentrations of Obeticholic acid (OCA) and Elafibranor (ELF) QD or vehicle control for 10 days, following an initial 4-day pre-culture phase. Throughout the compound dosing period TGFβ was also dosed onto all microtissues (NASH only vehicle control samples were also included in the study for comparison, which were not treated with TGFβ or dosed with any compound). a The secreted cytokine profile from treated liver microtissues was compared to determine the effects of each compound on the inflammatory profile of the liver with samples analysed at day 8 and 14 of the culture. Data were normalised by Z-transformation to allow comparison of all analytes (white = undetected). b The expression of fibrosis-associated biomarkers was analysed on day 14 media samples and compared to NASH + TGFβ control samples. c Liver microtissues were stained for collagen-type I, α-SMA, nuclei (DAPI), phalloidin (green) and imaged by confocal microscopy. Representative images are shown and scale bars 200 µm. Staining of microtissues was quantified by measuring total fluorescence intensity throughout individual microtissues, each data point represents an average of all microtissues per MPS culture (min 8, max 20). All datapoints shown with error bars highlighting means ± SD, all data from a minimum of three independent cultures: all comparisons were made to NASH + TGFβ control samples.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Cited by

See all 52

Metadata

Authors
Kostrzewski, T., Snow, S., Battle, A. L., Peel, S., Ahmad, Z., Basak, J., Surakala, M., Bornot, A., Lindgren, J., Ryaboshapkina, M., Clausen, M., Lindén, D., Maass, C., Young, L. M., Corrigan, A., Ewart, L., & Hughes, D.
Affiliations
  • CN Bio Innovations (United Kingdom) (GB)
  • AstraZeneca (United Kingdom) (GB)
  • AstraZeneca (India) (IN)
  • AstraZeneca (Sweden) (SE)
Corresponding author
Kostrzewski, Tomasz
Venue
Communications Biology
Published
2021-09-15
Volume
4
Issue
1
Pages
1080-1080
ISSN
2399-3642 (ISSN-L)
OpenAlex
W3199014335
Cited by
52
References
73
Citations by year
2026: 14 · 2025: 8 · 2024: 15 · 2023: 7 · 2022: 7 · 2021: 1
FWCI
5.38
Type
journal article
Language
en
Open access
Licence
Locations
  • Communications Biology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Innovate UK (Ref: 103598)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
nonalcoholic steatohepatitis, liver fibrosis, microphysiological systems, in vitro disease model, co-culture, transcriptomics, inflammation, TGF-beta, lipopolysaccharide, dietary intervention, obeticholic acid, elafibranor, fibrosis biomarkers
MeSH terms
Animals, Disease Models, Animal, Humans, Liver Cirrhosis, Mice, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. https://app.cochat.ai/papers/10.1038/s42003-021-02616-x
The paper
Kostrzewski, T., Snow, S., Battle, A. L., Peel, S., Ahmad, Z., Basak, J., Surakala, M., Bornot, A., Lindgren, J., Ryaboshapkina, M., Clausen, M., Lindén, D., Maass, C., Young, L. M., Corrigan, A., Ewart, L., & Hughes, D. (2021). Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. Communications Biology. https://doi.org/10.1038/s42003-021-02616-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.